In contrast to those in JAK2-wild cancers, the mutation rate (both the non-silent and silent mutational rates) (P < 0.001, Fig. 2C and 2D) and neoantigen load (including SNV-derived neoantigens and indel-derived neoantigens) (P < 0.001, Fig. 2E, F) were remarkably greater in JAK2-mutated cancers, revealing that JAK2 mutation was associated with increased cancer immunogenicity. The gene discussed is JAK2; the disease is cancer.